[Las Vegas (USA) = AVING News] EverX Co., Ltd. (CEO Chan Yoon) participated in ‘CES 1’, the world’s largest IT and home appliance exhibition held in Las Vegas, USA from January 5th to 8th (local time). introduced ‘MORA’, a musculoskeletal disorder rehabilitation and exercise treatment solution based on the company’s pose-estimation AI technology.
EverX, established in August 2019, is a startup specializing in digital treatment solutions. Founder and CEO Chan Yoon, an orthopedic surgeon who graduated from Seoul National University College of Medicine, founded EverX with the vision of improving the unmet need for rehabilitation exercise therapy through digital technology, which he felt while treating actual patients.
At the CES digital healthcare exhibition hall, EverX introduced solutions targeting the remote treatment monitoring market for musculoskeletal diseases in the United States, starting with the Mora service, and accelerated its efforts to secure customers and partners to enter the U.S. market.
MORA (Mobile Orthopedic Rehabilitation Assistant) is a digital treatment solution that prescribes rehabilitation and exercise therapy based on AI technology and medical evidence specialized for musculoskeletal disorders. Patients can perform exercise therapy and evaluate musculoskeletal function through posture estimation AI technology regardless of location as long as they have a camera on a portable terminal. Officials explain that medical staff can prescribe rehabilitation and perform remote monitoring using AI technology, making it easier to reduce time and financial burden in rehabilitation exercise treatment and increase patient accessibility.
The MORA solution is being piloted in domestic hospitals and clinics, and is being used by some domestic companies as a solution to manage the musculoskeletal system of employees within the company.
EverEx is developing Korea’s first musculoskeletal disease digital treatment solution, MORA, and MORA-based digital treatment devices, with technology, medical, and commercialization experts such as AI, DTx, and cognitive therapy. Currently, EverX is conducting clinical trials to explore a digital treatment device based on MORA for the treatment of patients with patellofemoral pain syndrome. This is the first clinical trial in Korea to confirm the effectiveness and safety of digital treatment devices for musculoskeletal diseases.
CEO Yoon Chan of EverX said, “We are aiming to supply MORA services to U.S. medical institutions this year.” He added, “The U.S. is already active in the use of digital treatment devices in the field of rehabilitation exercise, and has a fee policy in place, so it is a positive opportunity.” “I look forward to results,” he said. In addition, “MORA treatment solution will fill the gap in rehabilitation exercise treatment and ultimately contribute to improving the health of patients,” he said. “We are moving forward so that many musculoskeletal patients can receive complete treatment with advanced technologies such as AI.” “I will go out,” he emphasized.
Following CES, EverX will participate in the Biotech Showcase 1 held during the JP Morgan Healthcare Conference in San Francisco, USA from January 9th to 11th, and begin its expansion into the US business by holding a company introduction presentation on the 2023th. We continue to take various steps for this purpose.
Meanwhile, ‘CES’, the world’s largest technology fair, is an exhibition where you can see the trends of the global home appliance industry at a glance. Hosted by the Consumer Technology Association (CTA), it is held every January in Las Vegas, USA. AVING News, which has covered CES for 1 consecutive years, has reported CES news around the world every year since 17, and has been selected as the ‘BEST OF CES’, which selects the best innovative products and technologies, and the ‘BEST OF’, which selects domestic innovative companies. ‘MADE IN KOREA’ was held. In addition, CES on-site issues were vividly conveyed through ‘AVING LIVE’.